Sana Biotechnology Competitors and Similar CompaniesClear all

Amyris's competitors and similar companies include Mirimus, Nuclera and Editas Medicine.
Amyris
Amyris
Amyris is a biotechnology company that develops chemical ingredients using microbial fermentation.
Mirimus
Mirimus
Mirimus is a company that specializes in biotech and preclinical CRO solutions based on genetical engineering.
Nuclera
Nuclera
Nuclera is a company that specializes in DNA synthesis.
Editas Medicine
Editas Medicine
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
Founding Date
Founding Date
2003
Founding Date
2010
Founding Date
2013
Founding Date
2013
Type
Type
Private
Type
Private
Type
Private
Type
Public
Tags
Locations
Locations
Emeryville, US HQ
Sao Paulo, BR
Locations
Brooklyn, US HQ
Locations
Cambridge, GB HQ
Locations
Cambridge, US HQ
Boulder, US
Cambridge, US
Employees
Employees
1,0031% decrease
Employees
63
Employees
1192% decrease
Employees
20816% increase

Financial

Revenue (est.)
Revenue (est.)
$269.8m (FY, 2022)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$40.5m (FY, 2025)
Net income
Net income
($543.4m) (FY, 2022)
Net income
N/A
Net income
N/A
Net income
($160.1m) (FY, 2025)

Funding

Latest funding round
Latest funding round
$ 34m (about 7 years ago)
Latest funding round
$ 2m (over 15 years ago)
Latest funding round
$ 10m (over 7 years ago)
Latest funding round
N/A
Total funding raised
Total funding raised
$ 551.9m
Total funding raised
N/A
Total funding raised
$ 11.3m
Total funding raised
$ 210m
For sources of this data, please see the company profile

View Company Profiles

Mirimus
HQ
Brooklyn, US
Employees
63

Mirimus is a company that specializes in biotech and preclinical CRO solutions based on genetical engineering.

View company
Nuclera
HQ
Cambridge, GB
Employees
119↓ 2% decrease

Nuclera is a company that specializes in DNA synthesis.

View company
Editas Medicine
HQ
Cambridge, US
Employees
208↑ 16% increase

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.

View company